期刊
EUROPACE
卷 17, 期 12, 页码 1848-1854出版社
OXFORD UNIV PRESS
DOI: 10.1093/europace/euu394
关键词
Acute myocardial infarction; Heart rate variability; Multipole analysis; Cardiovascular risk; Malignant arrhythmias; CARISMA
资金
- Medtronic Bakken Research Center, Maastricht, The Netherlands
- Cambridge Heart Inc., MA, USA
Aims Dyx is a new heart rate variability (HRV) density analysis specifically designed to identify patients at high risk for malignant ventricular arrhythmias. The aim of this study was to test if Dyx can improve risk stratification for malignant ventricular tachyarrhythmias and to test if the previously identified cut-off can be reproduced. Methods and Results This study included 248 patients from the CARISMA study with ejection fraction <= 40% after an acute myocardial infarction and an analysable 24 h Holter recording. All patients received an implantable cardiac monitor, which was used to diagnose the primary endpoint of near-fatal or fatal ventricular tachyarrhythmias likely preventable by an implantable cardioverter defibrillator (ICD), during a period of 2 years. ADyx <= 1.96was considered abnormal. The secondary endpoint was cardiovascular death. At enrolment 59 patients (24%) had a Dyx <= 1.96 and 20 experienced a primary end-point. A Dyx <= 1.96 was associated with a significantly increased risk for malignant arrhythmias [hazards ratio (HR) = 4.36 (1.81-10.52), P = 0.001] and cardiovascular death [ HR = 3.47 (1.38-8.74), P = 0.008]. Compared with important clinical risk parameters (age >70 years and QRS > 120 ms), Dyx <= 1.96 significantly added predictive value (P = 0.0066). Conclusions Dyx was a better predictor of ventricular tachyarrhythmias than the traditional measures of HRV and heart rate turbulence, particularly in the elderly. Dyx might be a useful tool for better selection of ICD candidates in the elderly population, since a normal Dyx in this group was associated with a very low risk for malignant ventricular arrhythmias.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据